Loyal, a company focused on developing drugs to extend the lifespan of dogs, has initiated a large-scale clinical trial to assess the efficacy of a novel medication. The study aims to determine if a daily chewable medication can extend lifespan and improve the quality of life for older dogs.
Trial Design and Eligibility
The clinical trial is designed for dogs aged 10 years or older, weighing 14 pounds or more. Participating owners must commit to a study lasting up to four years. The study involves administering a flavored chewable medication daily and completing brief surveys about the dog's quality of life. These surveys can be completed at the vet clinic or remotely via smartphone, tablet, or computer.
Study Requirements
Owners participating in the trial are required to transfer their dog's primary care to the designated study clinic. The trial protocol includes six clinic visits in the first year, followed by two visits per year for the remaining years of the study. This comprehensive approach allows for close monitoring of the dogs' health and response to the medication.
